Health Care [ 9/12 ] | Biotechnology [ 65/74 ]
NASDAQ | Common Stock
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -0.80 Increased by +26.61% | -0.60 Decreased by -33.09% |
| Dec 31, 24 | -0.81 Increased by +17.35% | -0.93 Increased by +12.86% |
| Oct 30, 24 | -0.91 Decreased by -13.75% | -0.91 Decreased by -0.39% |
| Jul 31, 24 | -1.03 Decreased by -47.14% | -1.07 Increased by +3.74% |
| May 2, 24 | -1.09 Decreased by -11.22% | -0.99 Decreased by -10.10% |
| Jan 9, 24 | -0.98 Decreased by -13.95% | -0.85 Decreased by -15.29% |
| Oct 30, 23 | -0.80 Decreased by -2.56% | -0.82 Increased by +2.44% |
| Jul 31, 23 | -0.70 Decreased by -18.64% | -0.88 Increased by +20.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -29.26 M Increased by +25.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.22 M Decreased by -80.14% | -29.30 M Increased by +16.00% | Decreased by -2.40 K% Decreased by -322.88% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -32.79 M Decreased by -15.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -37.28 M Decreased by -49.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -39.06 M Decreased by -34.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 6.14 M Increased by +N/A% | -34.88 M Decreased by -44.73% | Decreased by -567.96% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -28.43 M Decreased by -27.51% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -24.89 M Decreased by -44.23% | Decreased by N/A% Decreased by N/A% |